NF1 and malignant peripheral nerve sheath tumor: There is no current preclinical or clinical data for ALK monotherapy activity in pediatric MPNST and EGFR and ALK targeting could potentially encounter therapy resistance due to NF1 and SUZ12 loss-of- function mutations14.